Syndax Pharmaceuticals is a biopharmaceutical company that develops cancer treatment therapies. It has two lead product candidates, SNDX-5613 and SNDX-6352, in different clinical stages for MLLr and NPM1c AML, and cGVHD respectively. The company also has ongoing collaborative research and development agreements with National Cancer Institute and other groups.